Pfizer, Allergan deal dead, what could be next?

Chris Ratcliffe | Bloomberg | Getty Images A $160 billion merger between Pfizer and Allergan lay in tatters Wednesday and left experts contemplating whether more deals could be hit by new tax rules...

Loading.. Please wait